Cue Biopharma price target lowered to $4 from $8 at Stifel

Stifel lowered the firm’s price target on Cue Biopharma to $4 from $8 and keeps a Buy rating on the shares following management’s pausing of CUE-101/102 development to emphasize an increased focus on autoimmune disease. The firm’s target price change mostly represents delayed CUE-101 commercialization timelines and revised non-dilutive and dilutive financing assumptions, partially offset by lower operating expense assumptions, the analyst tells investors.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue